193 related articles for article (PubMed ID: 8280289)
1. Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
Horwitz JP; Massova I; Wiese TE; Wozniak AJ; Corbett TH; Sebolt-Leopold JS; Capps DB; Leopold WR
J Med Chem; 1993 Nov; 36(23):3511-6. PubMed ID: 8280289
[TBL] [Abstract][Full Text] [Related]
2. Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03.
Horwitz JP; Massova I; Wiese TE; Besler BH; Corbett TH
J Med Chem; 1994 Mar; 37(6):781-6. PubMed ID: 8145227
[TBL] [Abstract][Full Text] [Related]
3. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Sebolt JS; Scavone SV; Pinter CD; Hamelehle KL; Von Hoff DD; Jackson RC
Cancer Res; 1987 Aug; 47(16):4299-304. PubMed ID: 2440564
[TBL] [Abstract][Full Text] [Related]
4. Activity of the pyrazoloacridines against multidrug-resistant tumor cells.
Sebolt J; Havlick M; Hamelehle K; Nelson J; Leopold W; Jackson R
Cancer Chemother Pharmacol; 1989; 24(4):219-24. PubMed ID: 2752501
[TBL] [Abstract][Full Text] [Related]
5. 2-(aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines, a new class of anticancer agents.
Capps DB; Dunbar J; Kesten SR; Shillis J; Werbel LM; Plowman J; Ward DL
J Med Chem; 1992 Dec; 35(26):4770-8. PubMed ID: 1479579
[TBL] [Abstract][Full Text] [Related]
6. Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation.
Antonini I; Polucci P; Cola D; Bontemps-Gracz M; Pescalli N; Menta E; Martelli S
Anticancer Drug Des; 1996 Jun; 11(4):339-49. PubMed ID: 8679056
[TBL] [Abstract][Full Text] [Related]
7. Benzoflavonoids Structure Hinders Human Colon Cancer Clonogenicity.
Yong Y; Koh EJ; Ahn S; Kim BS; Lee YH; Shin SY; Lim Y
Med Chem; 2017; 13(2):168-175. PubMed ID: 27220561
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P; Wozniak AJ; Polin L; Capps D; Leopold WR; Werbel LM; Biernat L; Dan ME; Corbett TH
Cancer Res; 1990 Aug; 50(16):4900-5. PubMed ID: 2165850
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
10. Novel, potent, and selective 5-HT3 receptor antagonists based on the arylpiperazine skeleton: synthesis, structure, biological activity, and comparative molecular field analysis studies.
Anzini M; Cappelli A; Vomero S; Giorgi G; Langer T; Hamon M; Merahi N; Emerit BM; Cagnotto A; Skorupska M
J Med Chem; 1995 Jul; 38(14):2692-704. PubMed ID: 7629808
[TBL] [Abstract][Full Text] [Related]
11. Quantitative structure-activity relationships/comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halogenated estradiol derivatives.
Gantchev TG; Ali H; van Lier JE
J Med Chem; 1994 Nov; 37(24):4164-76. PubMed ID: 7990116
[TBL] [Abstract][Full Text] [Related]
12. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.
Raichurkar AV; Kulkarni VM
J Med Chem; 2003 Oct; 46(21):4419-27. PubMed ID: 14521406
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules.
Waller CL; Marshall GR
J Med Chem; 1993 Aug; 36(16):2390-403. PubMed ID: 8360884
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional quantitative structure activity relationship (QSAR) of cytotoxic active 3,5-diaryl-4,5-dihydropyrazole analogs: a comparative molecular field analysis (CoMFA) revisited study.
Hamad Elgazwy AS; Soliman DS; Atta-Allah SR; Ibrahim DA
Chem Cent J; 2012 May; 6(1):50. PubMed ID: 22647291
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
16. Activity of batracylin (NSC-320846) against solid tumors of mice.
Mucci-LoRusso P; Polin L; Bissery MC; Valeriote F; Plowman J; Luk GD; Corbett TH
Invest New Drugs; 1989 Nov; 7(4):295-306. PubMed ID: 2557298
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study.
Kulkarni SS; Kulkarni VM
J Med Chem; 1999 Feb; 42(3):373-80. PubMed ID: 9986707
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
19. Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis.
Harpalani AD; Snyder SW; Subramanyam B; Egorin MJ; Callery PS
Cancer Res; 1993 Feb; 53(4):766-71. PubMed ID: 8428356
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate.
Wang Y; Li L; Jiang W; Larrick JW
Bioorg Med Chem; 2005 Oct; 13(19):5592-9. PubMed ID: 16084097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
